MCK on NYSE

McKesson Corporation

Logo: Roggit, CC BY-SA 4.0, via Wikimedia Commons5

US healthcare company

McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees.3 From Wikipedia, CC BY-SA 4.0

$997.95 up 21.38 (2.19%)Price as of Oct 15, 2026 at 19:45 UTC

Last updated Oct 16, 2026.

Overview

$403.4BRevenue, fiscal 20266
$4.8BNet income, fiscal 20266
1833Founded1

Compare with Cencora, Cardinal Health or Herbalife, or pick any stock.

  • TickerMCK on NYSE1
  • Industryproduct distribution1
  • HeadquartersIrving1
  • Founded inNew York City1
  • Websitewww.mckesson.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address6555 State Highway 161, Irving, Tx 750397
  • Filer categoryLarge accelerated filer7
McKesson Plaza east side 1
Photo: BrokenSphere, CC BY-SA 3.0, via Wikimedia Commons9

McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK".3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

3.6%Gross margin6
1.5%Operating margin6
1.2%Net margin6
12.4%Revenue growth, 20266
$5.7BFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

North American Pharmaceutical brought in 84% of the revenue McKesson Corporation broke down this way in fiscal 2026.

  1. North American Pharmaceutical$336.7B684%up 11% from 2025
  2. Oncology And Multispecialty$48.4B612%up 31% from 2025
  3. Medical-Surgical Solutions$11.5B63%up 1% from 2025
  4. Prescription Technology Solutions$5.8B61%up 11% from 2025
Business segments by year
Business segments202420252026
North American Pharmaceutical$261.4B$304.5B$336.7B
Oncology And Multispecialty$30.5B$36.9B$48.4B
Medical-Surgical Solutions$11.3B$11.4B$11.5B
Prescription Technology Solutions$4.8B$5.2B$5.8B

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue97¢$388.9B
  • Selling, general and admin2¢$8.1B
  • Income tax0¢$1.1B
  • Profit1¢$4.8B

Out of $403.4B in revenue.6

Where each dollar of operating cash went, fiscal 2026

  • Capital spending7¢$436.0M
  • Dividends paid6¢$381.0M
  • Share buybacks77¢$4.8B
  • Kept or used elsewhere10¢$588.0M

Out of $6.2B of cash from operations.6

Financial statements

Revenue10111213146$403.4B in 2026+88% since 2019
0$200.0B$400.0B$600.0B2019: $214.3B$214.3B20192020: $231.1B$231.1B2020+8%2021: $238.2B$238.2B2021+3%2022: $264.0B$264.0B2022+11%2023: $276.7B$276.7B2023+5%2024: $309.0B$309.0B2024+12%2025: $359.1B$359.1B2025+16%2026: $403.4B$403.4B2026+12%
Gross profit10111213146$14.6B in 2026+24% since 2019
0$5.0B$10.0B$15.0B2019: $11.8B$11.8B20192020: $12.0B$12.0B2020+2%2021: $12.1B$12.1B2021+1%2022: $13.1B$13.1B2022+8%2023: $12.4B$12.4B2023−6%2024: $12.8B$12.8B2024+4%2025: $13.3B$13.3B2025+4%2026: $14.6B$14.6B2026+9%
Operating income10111213146$6.2B in 2026+601% since 2019
-$10.0B-$5.0B0$5.0B$10.0B2019: $886.0M$886.0M20192020: $2.5B$2.5B2020+181%2021: -$5.0B-$5.0B20212022: $2.0B$2.0B20222023: $4.4B$4.4B2023+115%2024: $3.9B$3.9B2024−11%2025: $4.4B$4.4B2025+13%2026: $6.2B$6.2B2026+40%
Net income10111213146$4.8B in 2026+13906% since 2019
-$5.0B-$2.5B0$2.5B$5.0B2019: $34.0M$34.0M20192020: $900.0M$900.0M2020+2547%2021: -$4.5B-$4.5B20212022: $1.1B$1.1B20222023: $3.6B$3.6B2023+220%2024: $3.0B$3.0B2024−16%2025: $3.3B$3.3B2025+10%2026: $4.8B$4.8B2026+45%

Every line of the income statement in the latest annual report, as filed.6

Period ending2026-03-312025-03-312024-03-31
Revenues$403.4B$359.1B$309.0B
Cost of sales-$388.9B-$345.7B-$296.1B
Gross profit$14.6B$13.3B$12.8B
Selling, distribution, general, and administrative expenses-$8.1B-$8.5B-$8.7B
Claims and litigation charges, net$3.0M-$108.0M-$147.0M
Restructuring, impairment, and related charges, net-$245.0M-$286.0M-$115.0M
Total operating expenses-$8.3B-$8.9B-$8.9B
Operating income$6.2B$4.4B$3.9B
Other income, net$236.0M$202.0M$132.0M
Interest expense-$247.0M-$265.0M-$252.0M
Income before income taxes$6.2B$4.4B$3.8B
Income tax expense-$1.1B-$878.0M-$629.0M
Net income$5.1B$3.5B$3.2B
Net income attributable to noncontrolling interests-$337.0M-$186.0M-$158.0M
Net income attributable to McKesson Corporation$4.8B$3.3B$3.0B
Diluted (in dollars per share)$38.38$25.72$22.39
Basic (in dollars per share)$38.55$25.86$22.54
Diluted (in shares)124.1M shares128.1M shares134.1M shares
Basic (in shares)123.6M shares127.4M shares133.2M shares

Compare McKesson Corporation with another company

The story

19th century

McKesson was founded in 1828 in New York City as Charles M. Olcott by Charles M. Olcott. It was later renamed Olcott, McKesson & Co. and John McKesson in 1833. The business began as an importer and wholesaler of botanical drugs. A third partner, Daniel Robbins, who joined the enterprise as it grew, and who previously "was an assistant to the original partners", was the "Robbins" when the company was renamed McKesson & Robbins following Olcott's death in 1853.

20th century

In 1938, the company was involved in the McKesson and Robbins scandal under CEO Phillip Musica. It was one of the most notorious business and accounting scandals of the 20th century, a watershed event that led to major changes in American auditing standards and securities regulations after being exposed in 1938. It was found that one fourth of the $86,556,270 assets of the company was just figures recorded to keep McKesson looking profitable while Musica, who was posing as F. Donald Coster, and his brothers stole the funds. The company was able to weather the crisis after an equity receivership.

In 1967, Foremost Dairies, a company founded by James Cash Penney, which was headquartered in San Francisco since 1954, acquired McKesson & Robbins in a hostile takeover to form Foremost-McKesson Inc. The Foremost dairy operations were sold in 1982 and the name changed to McKesson Corporation but headquarters remained in San Francisco.

In 1999, McKesson acquired medical information systems firm HBO & Company (HBOC). The combined firm operated as McKessonHBOC for two years. Accounting irregularities at HBOC reduced the company's share price by half and resulted in the dismissal and prosecution of many HBOC executives.

21st century

In 2001, the company's name reverted to McKesson. In the early 21st century, McKesson increased its market in medical technology through acquisitions, including Per Se Technologies and RelayHealth in 2006 and Practice Partner in 2007. On January 6, 2006, McKesson acquired NDCHealth Corporation.

In 2010, McKesson acquired the oncology and physician services company US Oncology, Inc. for $2.16 billion, which was integrated into the McKesson Specialty Health business. In April 2012, McKesson agreed to pay the United States $190M to settle allegations that it had inflated prices and overbilled Medicaid. Three months later, in July 2012, McKesson agreed to pay California and 28 other states $151M to settle allegations that it had inflated prices and overbilled Medicaid.

On June 24, 2013, The Wall Street Journal reported that McKesson Chairman and CEO John Hammergren's pension benefits of $159 million had set a record for "the largest pension on file for a current executive of a public company, and almost certainly the largest ever in corporate America". In 2013, PSS World Medical was acquired. In 2014, McKesson acquired Celesio to become one of the world's largest healthcare companies, with over $179 billion in annual revenue. In June 2016, McKesson announced plans to merge its IT business with Change Healthcare.

In 2017, McKesson was involved in many lawsuits against the state of Arkansas over the supply of vecuronium bromide. McKesson was under contract by Pfizer not to sell to any correctional facility that authorized and carried out capital punishment.

Read the full text

In November 2018, the company announced it would relocate its headquarters from San Francisco to Irving, Texas, effective April 1, 2019. Also in April 2019, Brian Tyler took over as CEO of the company.

In February 2020, McKesson Corp announced that it would part ways with Change Healthcare. McKesson gave up its ownership in the company and its three seats on the company's board of directors. In February 2025, the McKesson Corporation signed a definitive agreement to acquire 80% interest in PRISM Vision Holdings.

In August 2026, the company was hacked by ShinyHunters.

Opioid epidemic

In 2008, McKesson paid $13 million in fines for failing to report large orders of hydrocodone.

In January 2017, McKesson agreed to pay a $150 million civil penalty for alleged similar violations of the Controlled Substances Act regarding the distribution of opioids and another $150M to settle allegations that it had not done enough to track and stop suspicious opioid sales. The agreement also obligated McKesson to suspend all sales of controlled substances from its distribution centers in Colorado, Florida, Ohio, and Michigan for multiple years.

In May 2020, Attorney General of Oklahoma Michael J. Hunter sued McKesson in Bryan County District Court, alleging that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against Cardinal Health and AmerisourceBergen, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."

In January 2022, McKesson, AmerisourceBergen, Cardinal Health, and Johnson & Johnson agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.

COVID-19 pandemic

In August 2020, during the COVID-19 pandemic, the CDC and HHS selected McKesson as the US government's centralized distributor for COVID-19 vaccine doses and ancillary supply kits under Operation Warp Speed. The company has played a key role in distributing the Moderna and Johnson & Johnson vaccines while also distributing ancillary supply kits for these as well as for the Pfizer–BioNTech vaccine across the US (in addition to supporting the US government in efforts to send doses and kits abroad).

From Wikipedia’s article on McKesson, shared under CC BY-SA 4.0.8

Leadership

Who has led McKesson Corporation, and when. Pick a name to see everywhere that person has worked.

197019801990200020102020
Board members and other officers (13)

Products and brands

  • medication

Listed on Wikidata.1

McKesson Provider Technologies

McKesson Provider Technologies is the retail name for McKesson Technology Solutions; the software development division of McKesson. Their customer base in the United States includes 50% of all health systems, 20% of all physician practices, 25% of home care agencies, and 77% of health systems with more than 200 beds.

On June 20, 2005, McKesson Provider Technologies acquired Medcon, Ltd., an Israeli company which provides web-based cardiac image and information management solutions for heart centers, that includes: diagnostic digital image management, archiving, procedure reporting, and workflow management.

In October 2013, McKesson agreed to buy a 50% stake in Germany-based Celesio for $8.3 billion.

McKesson Medical Supplies and Equipment

McKesson Medical-Surgical (MMS) offers a large selection of national healthcare brands, along with McKesson's exclusive brand of medical products. Their online medical supply ordering platform serves the needs of physician offices, surgery centers, home health agencies, DMEs, labs, and long-term-care facilities. In 2015, McKesson Medical-Surgical opened its new headquarters in Richmond, Virginia. In May of 2025, McKesson announced it was planning to spin off its medical-surgical supplies unit into an independent company.

Read the full text

Health Mart pharmacy franchise

Health Mart, a network of over 4,000 independently owned and operated pharmacies, is a wholly owned subsidiary of McKesson Corporation, which owns the name "Health Mart". McKesson acquired Health Mart owner FoxMeyer in October 1996.

Former divisions

Mosswood Wine Company

McKesson operated the Mosswood Wine Company from 1978 until 1987 when the division was sold to maintain its focus on pharmaceuticals. The division was founded and run by wine writer Gerald Asher.

NDCHealth (Relay Health)

NDC (from the initials of its former identity as National Data Corporation) became NDC-Health Corp in 2001 following the spin-off of its payments division, Global Payments, in 2000. NDCHealth was acquired by McKesson in 2007 through the purchase of Per-Se Technologies at which time it began doing business as RelayHealth in 2007.

From Wikipedia’s article on McKesson, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Owners

Subsidiaries

  • Guardian
  • Health Mart
  • I.D.A.
  • McKesson Europe AG
  • Norsk Medisinaldepot
  • Remedy'sRx
  • Rexall
  • US Oncology Network

Also owns

  • McKesson Plaza

From Wikidata.1

Acquisitions

  1. Succeeded McKesson & Robbins Inc.1

Employees over time

  • 201668,0001

Former names

  • MCKESSON HBOC INCSep 10, 1999 to Aug 13, 20017

Timeline

  1. 2001New chief executive John Hammergren becomes CEO1
  2. 1833Founded Founded in New York City1

Recent filings

  1. Oct 6, 20268-K
  2. Sep 10, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  3. Aug 28, 20268-K
  4. Aug 11, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  5. Aug 11, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  6. Aug 10, 2026144
  7. Aug 10, 20263 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
  8. Aug 5, 20268-K
  9. Aug 5, 202610-Q
  10. Aug 3, 2026144
  11. Jul 24, 20268-K
  12. Jul 23, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  13. Jul 23, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  14. Jul 23, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
  15. Jul 23, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2